A Phase 2 interventional study of Maraviroc in Human Immunodeficiency Virus, sponsored by ViiV Healthcare. Status unknown at 41 sites in 9 countries. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2020-04-28.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary purpose of this study is to determine the pharmacokinetic properties (what the body does to maraviroc) and to determine a suitable dosing schedule of maraviroc in HIV-1 infected children and adolescents. This study will also determine whether maraviroc is safe to use in children and adolescents.
3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.
This study's enrollment of 103 is close to the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Browse Acquired Immunodeficiency Syndrome studies →ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will be stratified by age and formulation into one of the following cohorts: Cohort 1: ≥2-\<6 years of age, maraviroc liquid formulation; Cohort 2: ≥6-\<12 years of age, maraviroc tablet formulation; Cohort 3: ≥6-\<12 years of age, maraviroc liquid formulation and Cohort 4: ≥12-\<18 years of age, maraviroc tablet formulation.
Drug: Maraviroc
Maraviroc will be administered twice daily either as a liquid or tablet formulation, depending on the age of the subject. The dosage administered will be dependent upon the subject's body surface area as well as the background therapy.
Also known as: Selzentry
Pharmacokinetic(PK): Maraviroc PK Parameter, Average Plasma Concentration (Cavg), Trough Concentration(Cmin), Maximum Plasma Concentration (Cmax)
Cavg: calculated as area under the curve divided by a dosing interval of 12 hours. Cmin: directly observed plasma concentration prior to the next dose. Geometric Coefficient of Variation is defined as the geometric standard deviation to the power of the reciprocal of the geometric mean.
Time frame: Week 2 and Week 48 (0, 1, 2, 4, 6, 8, 12 hours post-dose)
Area Under the Curve at Steady State (AUCtau)
AUCtau is the area under the plasma concentration time curve (AUC) at steady state from time zero (pre-dose) to end of dosing interval (tau), here dosing interval is 12 hours.
Time frame: Week 2 and Week 48 (0, 1, 2, 4, 6, 8, 12 hours post-dose)
Time to Reach Maximum Plasma Concentration (Tmax)
Time frame: Week 2 and Week 48 (0, 1, 2, 4, 6, 8, 12 hours post-dose)
Incidence and Severity of Grade 3 and Grade 4 Treatment-Emergent Adverse Events(AEs) (All Causality)
Incidence is reported in terms of number of events of AEs. The investigator used the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric AEs as follows: Grade 1= Symptoms causing no or minimal interference with usual social and functional activities; Grade 2= Symptoms causing greater than minimal interference with usual social and functional activities; Grade 3= Symptoms causing inability to perform usual social and functional activities; Grade 4= Symptoms causing inability to perform basic self-care functions or medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death. Data have been reported in the measure for Grade 3 and 4 as per system organ class and preferred term.
Time frame: Baseline up to 5 years
Treatment Discontinuation: Secondary Reasons- Serious Adverse Event (SAE) Related to Study Drug
The primary reason for a participant discontinuing from study drug or the clinical study was recorded in the source documents as well as the case report form. A discontinuation had to be reported immediately to the study medical monitor or his/her designated representative if it was due to an SAE and was considered as a secondary reason.
Time frame: Baseline up to 5 years
Percentage of Participants With HIV-1 RNA <400 Copies/mL Through Week 48 Using Missing, Discontinuation = Failure (MD=F) Approach
The proportion of participants who achieved HIV-1 RNA \<400 copies/mL at week 24 or 48 was assessed according to Food and Drug Administration's (FDA's) Missing, Switch, Discontinuation'=Failure (MSDF) Snapshot algorithm. The algorithm uses the plasma HIV-1 RNA in the Week 24 or 48 visit window, follows the "virology-first principle" and considers a participant who has a missing plasma HIV-1 RNA, or switches to prohibited ARV regimen or discontinues from the study or study drug for any reason, or dies, as a failure.
Time frame: Week 24 and Week 48 post-treatment
Percentage of Participants With HIV-1 RNA <48 Copies/mL Through Week 48 Using Missing, Discontinuation = Failure (MD=F)Approach
The proportion of participants who achieved HIV-1 RNA \<48 copies/mL at week 24 or 48 was assessed according to Food and Drug Administration's (FDA's) Missing, Switch, Discontinuation'=Failure (MSDF) Snapshot algorithm. The algorithm uses the plasma HIV-1 RNA in the Week 24 or 48 visit window, follows the "virology-first principle" and considers a participant who has a missing plasma HIV-1 RNA, or switches to prohibited ARV regimen or discontinues from the study or study drug for any reason, or dies, as a failure.
Time frame: Week 24 and Week 48 post-treatment
Percentage of Participants With HIV-1 RNA Levels <400 Copies/mL at Weeks 24 and 48 Using Missing, Discontinuation = Failure (MD=F)Approach
Participants who have been discontinued from the study, have been lost to follow-up, or have missing HIV-1 RNA data prior to the time point of interest were considered to have HIV-1 RNA levels \> lower limit of quantification (LLOQ) . This referred to as \[non-completer = failure; NC=F\] or \[missing, discontinuation = failure; MD=F\].
Time frame: Week 24 and Week 48 post-treatment
Percentage of Participants With HIV-1 RNA Levels < 48 Copies/mL at Weeks 24 and 48 Using MD=F Approach
Participants who have been discontinued from the study, have been lost to follow-up, or have missing HIV-1 RNA data prior to the time point of interest were considered to have HIV-1 RNA levels \> lower limit of quantification (LLOQ) . This referred as \[non-completer = failure; NC=F\] or \[missing, discontinuation = failure; MD=F\].
Time frame: Week 24 and Week 48 post-treatment
Percentage of Participants With HIV-1 RNA <400 Copies/mL and <48 Copies/mL Using the Time to Loss of Virologic Response Algorithm (TLOVR) at Week 48
TLOVR is defined as the time from first dose of study medication (Day 1) until the time of virologic failure using the a TLOVR algorithm.
Time frame: Week 48
Percentage of Participants With >= 1.0 log10 Reduction in HIV-1RNA Concentration From Baseline to Week 24 and Week 48
Percentage of participants with at least a 1.0 log10 reduction in HIV-1 RNA from baseline to Week 24 and Week 48 were tabulated.
Time frame: Baseline to Week 24, Week 48 post-treatment
Change From Baseline in HIV-1 RNA (Original)
Plasma HIV-1 RNA was determined using the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Test (lower limit of quantification \[LLOQ\] \<48 copies/mL). Blood samples were taken at the time points indicated in the participant evaluation schedule. Screening HIV-1 RNA \>1000 copies/ml was used to determine eligibility for the study.
Time frame: Baseline, Week 24, Week 48 post-treatment
Change From Baseline in HIV-1 RNA (Log10 Copies/mL)
Plasma HIV-1 RNA was determined using the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Test (lower limit of quantification \[LLOQ\] \<48 copies/mL). Blood samples were taken at the time points indicated in the participant evaluation schedule. Screening HIV-1 RNA \>1000 copies/ml was used to determine eligibility for the study.
Time frame: Baseline, Week 24, Week 48 post-treatment
Change From Baseline in Cluster of Differentiation 4 (CD4+) Cell Count at Weeks 24 and 48
Change from baseline in CD4 cell count to Week 24 and Week 48 were tabulated in aggregated and broken down by age cohort using summary statistics.
Time frame: Baseline, Week 24, Week 48 post-treatment
Change From Baseline in Percentage (%) of CD4+ Cells at Weeks 24 and 48
Change from baseline in CD4 % to Week 24 and Week 48 were tabulated in aggregated and broken down by age cohort using summary statistics.
Time frame: Baseline, Week 24 and Week 48 post-treatment
Number of Participants With Protocol Defined Virologic Failure
The occurrence of any one of the following criteria would constitute Virologic failure: Criteria A=Decrease from Baseline plasma HIV-1 RNA \<1 log10 and plasma HIV-1 RNA \>400 copies/mL starting at Week 12 and confirmed at consecutive Week 16; Criteria B=Decrease from Baseline plasma HIV-1 RNA \<2.0 log10 and plasma HIV-1 RNA \>400 copies/mL at Week 24 OR plasma HIV-1 RNA \>10,000 copies/mL on and after Week 24, and confirmed within 14 to 21 days; Criteria C=Increase from nadir plasma HIV-1 RNA of \>=1 log10 (\>=1,000 copies/mL if nadir plasma HIV-1 RNA \<48 copies/mL) at any time, and confirmed within 14 to 21 days.
Time frame: Week 48
Number of Participants With Viral Tropism Between Screening and Confirmed Protocol Defined Virologic Failure (PDVF) Prior to Week 48
Virus tropism was determined using the Monogram Biosciences Trofile™ viral tropism assay. Change in detected tropism from screening to the time of failure prior to Week 48 was reported. X4=CXCR4 tropic virus; R5=CCR5-tropic virus; X4=CXCR4-tropic virus. Number of participants as per tropism to respective virus has been reported.
Time frame: Screening to Week 48
Number of Participants With Emergence of Reverse Transcriptase Inhibitor (RTI) and Protease Inhibitor (PI) Resistance Associated Mutations (RAMs) Between Screening and On-Treatment Confirmed PDVF
Phenotypic and genotypic susceptibility to reverse transcriptase and protease inhibitors was evaluated at screening using the Monogram Biosciences PhenoSense™ GT (PSGT) assay. Samples from a confirmatory PDVF visit or early termination of MVC were planned to be analyzed if the plasma HIV-1 RNA was ≥400 copies/mL. Data for participants with respective gene mutation category has been reported. Participants with more than one mutation are counted more than once.
Time frame: 48 weeks
Percentage of Participants With Optimized Background Treatment Susceptibility Scores
Data was summarized by the total ARV activity of the background regimen using simple and weighted total optimized background treatment susceptibility scores as well as by screening genotype. Simple total optimized background treatment (OBT) susceptibility scores were categorized as 0, 1, \>=2 and weighted total OBT susceptibility scores were categorized as 0 to 0.5, 1 to 1.5 and \>=2. However, net susceptibility scores were imputed for simple analysis based on genotype. Susceptibility scores indicate the level resistance to the study medication. Scores ranged from 0 to 1 as 1 = susceptible and potential low-level resistance; 0.5 = low and intermediate-level resistance; 0 = high-level resistance, where higher scores indicated lower resistance.
Time frame: 48 weeks
This open-label, multicenter, multiple dose pharmacokinetic, safety and efficacy study at 24 sites in 8 countries.
| Milestone | >=2 - <6 Years of Age, MVC Liquid Formulation | >=6 - <12 Years of Age, MVC Tablet Formulation | >=6 - <12 Years of Age, MVC Liquid Formulation | >=12 - <18 Years of Age, MVC Tablet Formulation |
|---|---|---|---|---|
| Started | 16 | 31 | 13 | 43 |
| Completed | 10 | 20 | 7 | 13 |
| Not completed | 6 | 11 | 6 | 30 |
| Withdrew: Insufficient clinical response | 1 | 4 | 1 | 8 |
| Withdrew: No longer willing to participate | 1 | 1 | 0 | 8 |
| Withdrew: Non-compliance with study treatment | 0 | 2 | 0 | 4 |
| Withdrew: Withdrawn due to pregnancy | 0 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 1 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 4 | 3 | 4 | 6 |
| Withdrew: Adverse event | 0 | 0 | 1 | 1 |
Cavg: calculated as area under the curve divided by a dosing interval of 12 hours. Cmin: directly observed plasma concentration prior to the next dose. Geometric Coefficient of Variation is defined as the geometric standard deviation to the power of the reciprocal of the geometric mean.
| nanogram per milliliter (ng/mL) | >=2 - <6 Years of Age, MVC Liquid Formulation | >=6 - <12 Years of Age, MVC Tablet Formulation | >=6 - <12 Years of Age, MVC Liquid Formulation | >=12 - <18 Years of Age, MVC Tablet Formulation |
|---|---|---|---|---|
| Cavg-Week2 | 237.34 ± 63 | 260.65 ± 43 | 264.45 ± 62 | 239.85 ± 67 |
| Cavg-Week 48 | 163.73 ± 146 | 289.69 ± 50 | 168.62 ± 117 | 199.12 ± 78 |
| Cmax-Week2 | 581.47 ± 69 | 546.80 ± 51 | 444.37 ± 61 | 530.80 ± 62 |
| Cmax-Week 48 | 334.68 ± 156 | 593.68 ± 25 | 284.96 ± 128 | 423.32 ± 48 |
| Cmin-Week2 | 18.97 ± 202208 | 100.02 ± 39 | 115.84 ± 90 | 56.17 ± 145 |
| Cmin-Week 48 | 48.11 ± 180 | 82.21 ± 120 | 60.03 ± 245 | 66.51 ± 140 |
AUCtau is the area under the plasma concentration time curve (AUC) at steady state from time zero (pre-dose) to end of dosing interval (tau), here dosing interval is 12 hours.
| ng*hr/mL | >=2 - <6 Years of Age, MVC Liquid Formulation | >=6 - <12 Years of Age, MVC Tablet Formulation | >=6 - <12 Years of Age, MVC Liquid Formulation | >=12 - <18 Years of Age, MVC Tablet Formulation |
|---|---|---|---|---|
| AUCtau - Week 2 | 2848.1 ± 63 | 3127.7 ± 43 | 3173.4 ± 62 | 2878.2 ± 67 |
| AUCtau - Week 48 | 1964.7 ± 146 | 3476.3 ± 50 | 2023.5 ± 117 | 2389.4 ± 78 |
| hour | >=2 - <6 Years of Age, MVC Liquid Formulation | >=6 - <12 Years of Age, MVC Tablet Formulation | >=6 - <12 Years of Age, MVC Liquid Formulation | >=12 - <18 Years of Age, MVC Tablet Formulation |
|---|---|---|---|---|
| Tmax - Week 2 | 2.000 (0.97 to 6.00) | 4.000 (0.75 to 6.00) | 2.000 (1.00 to 4.00) | 2.000 (1.00 to 4.00) |
| Tmax - Week 48 | 2.000 (0.00 to 6.03) | 2.000 (1.00 to 8.00) | 3.000 (0.00 to 6.00) | 2.000 (1.00 to 4.00) |
Incidence is reported in terms of number of events of AEs. The investigator used the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric AEs as follows: Grade 1= Symptoms causing no or minimal interference with usual social and functional activities; Grade 2= Symptoms causing greater than minimal interference with usual social and functional activities; Grade 3= Symptoms causing inability to perform usual social and functional activities; Grade 4= Symptoms causing inability to perform basic self-care functions or medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death. Data have been reported in the measure for Grade 3 and 4 as per system organ class and preferred term.
| events | Cohort 1 (Grade 3) | Cohort 1 (Grade 4) | Cohort 2 (Grade 3) | Cohort 2 (Grade 4) | Cohort 3 (Grade 3) | Cohort 3 (Grade 4) | Cohort 4 (Grade 3) | Cohort 4 (Grade 4) |
|---|---|---|---|---|---|---|---|---|
| Gastrointestinal disorders - Vomiting | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Hepat. disorders - Drug-induced liver injury | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Infections and infestations - H1N1 influenza | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Infections and infestations - Pneumonia | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| Investigations - Lipase increased | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pyschiatric disorder - Bipolar disorder | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Gastrointestinal disorders - Gastritis | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Investigations - Hepatic enzyme abnormal | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Investigations - Transaminases increased | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Pyschiatric disorder - Aggression | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Blood and lymphatic system disorders - Anaemia | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Infections and infestations - Meningitis | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Infections and infestations -Otitis media | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
The primary reason for a participant discontinuing from study drug or the clinical study was recorded in the source documents as well as the case report form. A discontinuation had to be reported immediately to the study medical monitor or his/her designated representative if it was due to an SAE and was considered as a secondary reason.
| participants | >=2 - <6 Years of Age, MVC Liquid Formulation | >=6 - <12 Years of Age, MVC Tablet Formulation | >=6 - <12 Years of Age, MVC Liquid Formulation | >=12 - <18 Years of Age, MVC Tablet Formulation |
|---|---|---|---|---|
| Treatment Discontinuation: Secondary Reasons- Serious Adverse Event (SAE) Related to Study Drug | 0 | 0 | 0 | 0 |
The proportion of participants who achieved HIV-1 RNA \<400 copies/mL at week 24 or 48 was assessed according to Food and Drug Administration's (FDA's) Missing, Switch, Discontinuation'=Failure (MSDF) Snapshot algorithm. The algorithm uses the plasma HIV-1 RNA in the Week 24 or 48 visit window, follows the "virology-first principle" and considers a participant who has a missing plasma HIV-1 RNA, or switches to prohibited ARV regimen or discontinues from the study or study drug for any reason, or dies, as a failure.
| percentage of participants | >=2 - <6 Years of Age, MVC Liquid Formulation | >=6 - <12 Years of Age, MVC Tablet Formulation | >=6 - <12 Years of Age, MVC Liquid Formulation | >=12 - <18 Years of Age, MVC Tablet Formulation |
|---|---|---|---|---|
| Week 24 | 68.8 | 90.3 | 69.2 | 62.8 |
| Week 48 | 75.0 | 77.4 | 69.2 | 51.2 |
The proportion of participants who achieved HIV-1 RNA \<48 copies/mL at week 24 or 48 was assessed according to Food and Drug Administration's (FDA's) Missing, Switch, Discontinuation'=Failure (MSDF) Snapshot algorithm. The algorithm uses the plasma HIV-1 RNA in the Week 24 or 48 visit window, follows the "virology-first principle" and considers a participant who has a missing plasma HIV-1 RNA, or switches to prohibited ARV regimen or discontinues from the study or study drug for any reason, or dies, as a failure.
| percentage of participants | >=2 - <6 Years of Age, MVC Liquid Formulation | >=6 - <12 Years of Age, MVC Tablet Formulation | >=6 - <12 Years of Age, MVC Liquid Formulation | >=12 - <18 Years of Age, MVC Tablet Formulation |
|---|---|---|---|---|
| Week 24 | 18.75 | 64.5 | 61.5 | 48.8 |
| Week 48 | 50.0 | 54.8 | 53.8 | 39.5 |
Participants who have been discontinued from the study, have been lost to follow-up, or have missing HIV-1 RNA data prior to the time point of interest were considered to have HIV-1 RNA levels \> lower limit of quantification (LLOQ) . This referred to as \[non-completer = failure; NC=F\] or \[missing, discontinuation = failure; MD=F\].
| Percentage of participants | >=2 - <6 Years of Age, MVC Liquid Formulation | >=6 - <12 Years of Age, MVC Tablet Formulation | >=6 - <12 Years of Age, MVC Liquid Formulation | >=12 - <18 Years of Age, MVC Tablet Formulation |
|---|---|---|---|---|
| Week 24 | 62.5 (38.8 to 86.2) | 87.10 (75.3 to 98.9) | 69.2 (44.1 to 94.3) | 62.8 (48.3 to 77.2) |
| Week 48 | 75.0 (53.8 to 96.2) | 74.2 (58.8 to 89.6) | 69.2 (44.1 to 94.3) | 51.2 (36.2 to 66.1) |
Participants who have been discontinued from the study, have been lost to follow-up, or have missing HIV-1 RNA data prior to the time point of interest were considered to have HIV-1 RNA levels \> lower limit of quantification (LLOQ) . This referred as \[non-completer = failure; NC=F\] or \[missing, discontinuation = failure; MD=F\].
| Percentage of participants | >=2 - <6 Years of Age, MVC Liquid Formulation | >=6 - <12 Years of Age, MVC Tablet Formulation | >=6 - <12 Years of Age, MVC Liquid Formulation | >=12 - <18 Years of Age, MVC Tablet Formulation |
|---|---|---|---|---|
| Week 24 | 18.8 (0.0 to 37.9) | 64.5 (47.7 to 81.4) | 61.5 (35.1 to 89.0) | 48.8 (33.9 to 63.8) |
| Week 48 | 50.0 (25.5 to 74.5) | 54.8 (34.0 to 69.2) | 53.8 (35.1 to 89.0) | 39.5 (24.9 to 54.2) |
TLOVR is defined as the time from first dose of study medication (Day 1) until the time of virologic failure using the a TLOVR algorithm.
| Percentage of participants | >=2 - <6 Years of Age, MVC Liquid Formulation | >=6 - <12 Years of Age, MVC Tablet Formulation | >=6 - <12 Years of Age, MVC Liquid Formulation | >=12 - <18 Years of Age, MVC Tablet Formulation |
|---|---|---|---|---|
| <400 copies/mL; TLOVR Responder | 62.5 | 74.2 | 69.2 | 48.8 |
| <48 copies/mL; TLOVR Responder | 43.8 | 54.8 | 46.2 | 44.2 |
Percentage of participants with at least a 1.0 log10 reduction in HIV-1 RNA from baseline to Week 24 and Week 48 were tabulated.
| percentage of participants | >=2 - <6 Years of Age, MVC Liquid Formulation | >=6 - <12 Years of Age, MVC Tablet Formulation | >=6 - <12 Years of Age, MVC Liquid Formulation | >=12 - <18 Years of Age, MVC Tablet Formulation |
|---|---|---|---|---|
| Baseline to Week 24 | 92.3 (77.8 to 106.8) | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) | 93.1 (83.9 to 102.3) |
| Baseline to Week 48 | 100.0 (100.0 to 100.0) | 96.2 (88.8 to 103.6) | 100.0 (100.0 to 100.0) | 88.0 (75.3 to 100.7) |
Plasma HIV-1 RNA was determined using the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Test (lower limit of quantification \[LLOQ\] \<48 copies/mL). Blood samples were taken at the time points indicated in the participant evaluation schedule. Screening HIV-1 RNA \>1000 copies/ml was used to determine eligibility for the study.
| copies/mL | >=2 - <6 Years of Age, MVC Liquid Formulation | >=6 - <12 Years of Age, MVC Tablet Formulation | >=6 - <12 Years of Age, MVC Liquid Formulation | >=12 - <18 Years of Age, MVC Tablet Formulation |
|---|---|---|---|---|
| Change from Baseline - Original - Week 24 | -271974.6 ± 391843.59 | -38764.0 ± 63688.93 | -58081.0 ± 79720.33 | -57325.7 ± 172108.62 |
| Change from Baseline - Original - Week 48 | -267834.2 ± 378896.88 | -34787.7 ± 60222.60 | -56351.7 ± 76231.03 | -55321.1 ± 173840.55 |
Plasma HIV-1 RNA was determined using the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Test (lower limit of quantification \[LLOQ\] \<48 copies/mL). Blood samples were taken at the time points indicated in the participant evaluation schedule. Screening HIV-1 RNA \>1000 copies/ml was used to determine eligibility for the study.
| Log10 Copies/mL | >=2 - <6 Years of Age, MVC Liquid Formulation | >=6 - <12 Years of Age, MVC Tablet Formulation | >=6 - <12 Years of Age, MVC Liquid Formulation | >=12 - <18 Years of Age, MVC Tablet Formulation |
|---|---|---|---|---|
| Change from Baseline - Log10 - Week 24 | -2.4853 ± 1.1421 | -2.2324 ± 0.8668 | -2.1756 ± 1.1854 | -1.6482 ± 1.3806 |
| Change from Baseline - Log10 - Week 48 | -2.5831 ± 1.2148 | -1.9579 ± 1.0861 | -2.0549 ± 1.2125 | -1.4591 ± 1.4477 |
Change from baseline in CD4 cell count to Week 24 and Week 48 were tabulated in aggregated and broken down by age cohort using summary statistics.
| cells/mm^3 | >=2 - <6 Years of Age, MVC Liquid Formulation | >=6 - <12 Years of Age, MVC Tablet Formulation | >=6 - <12 Years of Age, MVC Liquid Formulation | >=12 - <18 Years of Age, MVC Tablet Formulation |
|---|---|---|---|---|
| Week 24 | 232.7 ± 381.6 | 355.8 ± 294.0 | 213.9 ± 166.4 | 173.6 ± 203.6 |
| Week 48 | 275.9 ± 363.4 | 362.7 ± 373.5 | 167.3 ± 150.9 | 168.6 ± 211.0 |
Change from baseline in CD4 % to Week 24 and Week 48 were tabulated in aggregated and broken down by age cohort using summary statistics.
| percentage of CD4+ cells | >=2 - <6 Years of Age, MVC Liquid Formulation | >=6 - <12 Years of Age, MVC Tablet Formulation | >=6 - <12 Years of Age, MVC Liquid Formulation | >=12 - <18 Years of Age, MVC Tablet Formulation |
|---|---|---|---|---|
| Week 24 | 7.3 ± 5.0 | 3.8 ± 7.4 | 3.5 ± 4.0 | 3.8 ± 6.1 |
| Week 48 | 7.5 ± 7.6 | 6.0 ± 6.8 | 2.5 ± 4.2 | 4.6 ± 6.5 |
The occurrence of any one of the following criteria would constitute Virologic failure: Criteria A=Decrease from Baseline plasma HIV-1 RNA \<1 log10 and plasma HIV-1 RNA \>400 copies/mL starting at Week 12 and confirmed at consecutive Week 16; Criteria B=Decrease from Baseline plasma HIV-1 RNA \<2.0 log10 and plasma HIV-1 RNA \>400 copies/mL at Week 24 OR plasma HIV-1 RNA \>10,000 copies/mL on and after Week 24, and confirmed within 14 to 21 days; Criteria C=Increase from nadir plasma HIV-1 RNA of \>=1 log10 (\>=1,000 copies/mL if nadir plasma HIV-1 RNA \<48 copies/mL) at any time, and confirmed within 14 to 21 days.
| participants | >=2 - <6 Years of Age, MVC Liquid Formulation | >=6 - <12 Years of Age, MVC Tablet Formulation | >=6 - <12 Years of Age, MVC Liquid Formulation | >=12 - <18 Years of Age, MVC Tablet Formulation |
|---|---|---|---|---|
| Criteria A | 0 | 2 | 1 | 5 |
| Criteria B | 0 | 0 | 0 | 0 |
| Criteria C | 3 | 3 | 2 | 8 |
Virus tropism was determined using the Monogram Biosciences Trofile™ viral tropism assay. Change in detected tropism from screening to the time of failure prior to Week 48 was reported. X4=CXCR4 tropic virus; R5=CCR5-tropic virus; X4=CXCR4-tropic virus. Number of participants as per tropism to respective virus has been reported.
| participants | >=2 - <6 Years of Age, MVC Liquid Formulation | >=6 - <12 Years of Age, MVC Tablet Formulation | >=6 - <12 Years of Age, MVC Liquid Formulation | >=12 - <18 Years of Age, MVC Tablet Formulation |
|---|---|---|---|---|
| With valid on-treatment results | 2 | 4 | 3 | 11 |
| Tropism at Confirmed PDVF R5 | 2 | 3 | 2 | 9 |
| Tropism at Confirmed PDVF DM | 0 | 1 | 1 | 2 |
| Tropism at Confirmed PDVF X4 | 0 | 0 | 0 | 0 |
| Tropism at Confirmed PDVF Not Reportable | 1 | 0 | 0 | 1 |
Phenotypic and genotypic susceptibility to reverse transcriptase and protease inhibitors was evaluated at screening using the Monogram Biosciences PhenoSense™ GT (PSGT) assay. Samples from a confirmatory PDVF visit or early termination of MVC were planned to be analyzed if the plasma HIV-1 RNA was ≥400 copies/mL. Data for participants with respective gene mutation category has been reported. Participants with more than one mutation are counted more than once.
| participants | >=2 - <6 Years of Age, MVC Liquid Formulation | >=6 - <12 Years of Age, MVC Tablet Formulation | >=6 - <12 Years of Age, MVC Liquid Formulation | >=12 - <18 Years of Age, MVC Tablet Formulation |
|---|---|---|---|---|
| With valid on-treatment results | 2 | 4 | 3 | 11 |
| PI Minor L10L/F | 0 | 0 | 0 | 1 |
| PI Minor L89L/I/M | 0 | 0 | 0 | 1 |
| PI Minor V77V/I | 0 | 0 | 0 | 1 |
| NNRTI K103K/N | 0 | 1 | 0 | 0 |
| NNRTI K103N | 0 | 0 | 1 | 1 |
| NRTI M184V | 0 | 0 | 1 | 0 |
| PI Minor K20K/R | 0 | 0 | 2 | 0 |
| Total with emergence | 0 | 1 | 3 | 4 |
Data was summarized by the total ARV activity of the background regimen using simple and weighted total optimized background treatment susceptibility scores as well as by screening genotype. Simple total optimized background treatment (OBT) susceptibility scores were categorized as 0, 1, \>=2 and weighted total OBT susceptibility scores were categorized as 0 to 0.5, 1 to 1.5 and \>=2. However, net susceptibility scores were imputed for simple analysis based on genotype. Susceptibility scores indicate the level resistance to the study medication. Scores ranged from 0 to 1 as 1 = susceptible and potential low-level resistance; 0.5 = low and intermediate-level resistance; 0 = high-level resistance, where higher scores indicated lower resistance.
| Percentage of participants | Response | PDVF | Other Failure/Remainder |
|---|---|---|---|
| Simple score 0 | 0 | 0 | 0 |
| Simple score 1.0 | 8.2 | 4.3 | 0 |
| Simple score >=2.0 | 81.6 | 95.7 | 96.8 |
| Weighted score 0-0.5 | 6.1 | 30.4 | 29.0 |
| Weighted score 1.0-1.5 | 53.1 | 65.2 | 29.0 |
| Weighted score >=2.0 | 28.6 | 4.3 | 38.7 |
Collected over Baseline up to 5 years. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| >=2 - <6 Years of Age, MVC Liquid Formulation | 0/16 (0%) | 5/16 (31.3%) | 12/16 (75%) |
| >=6 - <12 Years of Age, MVC Tablet Formulation | 0/31 (0%) | 5/31 (16.1%) | 25/31 (80.6%) |
| >=6 - <12 Years of Age, MVC Liquid Formulation | 0/13 (0%) | 3/13 (23.1%) | 10/13 (76.9%) |
| >=12 - <18 Years of Age, MVC Tablet Formulation | 1/43 (2.3%) | 10/43 (23.3%) | 34/43 (79.1%) |
| Event | >=2 - <6 Years of Age, MVC Liquid Formulation | >=6 - <12 Years of Age, MVC Tablet Formulation | >=6 - <12 Years of Age, MVC Liquid Formulation | >=12 - <18 Years of Age, MVC Tablet Formulation |
|---|---|---|---|---|
| Gastric fistulaGastrointestinal disorders | 0/16 | 0/31 | 1/13 | 0/43 |
| PneumoniaInfections and infestations | 0/16 | 1/31 | 1/13 | 2/43 |
| OsteopeniaMusculoskeletal and connective tissue disorders | 0/16 | 0/31 | 1/13 | 0/43 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/16 | 0/31 | 1/13 | 0/43 |
| PrurigoSkin and subcutaneous tissue disorders | 0/16 | 0/31 | 1/13 | 0/43 |
| VomitingGastrointestinal disorders | 1/16 | 0/31 | 0/13 | 0/43 |
| Abscess oralInfections and infestations | 1/16 | 0/31 | 0/13 | 0/43 |
| Tooth abscessInfections and infestations | 1/16 | 0/31 | 0/13 | 0/43 |
| OtorrhoeaEar and labyrinth disorders | 1/16 | 0/31 | 0/13 | 0/43 |
| ConstipationGastrointestinal disorders | 1/16 | 0/31 | 0/13 | 0/43 |
| Event | >=2 - <6 Years of Age, MVC Liquid Formulation | >=6 - <12 Years of Age, MVC Tablet Formulation | >=6 - <12 Years of Age, MVC Liquid Formulation | >=12 - <18 Years of Age, MVC Tablet Formulation |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 7/16 | 3/31 | 4/13 | 9/43 |
| Upper respiratory tract infectionInfections and infestations | 7/16 | 6/31 | 2/13 | 5/43 |
| VomitingGastrointestinal disorders | 6/16 | 8/31 | 3/13 | 4/43 |
| Otitis mediaInfections and infestations | 6/16 | 1/31 | 1/13 | 0/43 |
| NasopharyngitisInfections and infestations | 4/16 | 4/31 | 0/13 | 3/43 |
| InfluenzaInfections and infestations | 2/16 | 6/31 | 3/13 | 5/43 |
| Viral upper respiratory tract infectionInfections and infestations | 3/16 | 2/31 | 3/13 | 1/43 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/16 | 6/31 | 2/13 | 3/43 |
| BronchitisInfections and infestations | 3/16 | 3/31 | 0/13 | 7/43 |
| GastroenteritisInfections and infestations | 3/16 | 0/31 | 2/13 | 2/43 |
The Full Analysis Set (FAS) consisted of all participants who received at least 1 dose of study drug.
| Age, Continuous(Years) | >=2 - <6 Years of Age, MVC Liquid Formulation | >=6 - <12 Years of Age, MVC Tablet Formulation | >=6 - <12 Years of Age, MVC Liquid Formulation | >=12 - <18 Years of Age, MVC Tablet Formulation | Total |
|---|---|---|---|---|---|
| Mean | 3.4 ± 0.9 | 9.1 ± 1.7 | 8.9 ± 2.0 | 14.0 ± 1.6 | 10.3 ± 4.1 |
| Sex: Female, Male(Participants) | >=2 - <6 Years of Age, MVC Liquid Formulation | >=6 - <12 Years of Age, MVC Tablet Formulation | >=6 - <12 Years of Age, MVC Liquid Formulation | >=12 - <18 Years of Age, MVC Tablet Formulation | Total |
|---|---|---|---|---|---|
| Female | 5 | 16 | 6 | 27 | 54 |
| Male | 11 | 15 | 7 | 16 | 49 |
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Apr 2009 to primary completion in Apr 2015, 71 months.
Results were first posted in Feb 2016, 10 months after primary completion.
Of 29 industry-sponsored phase 2 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's 71 months is above that.
Counting every sponsor, half of 86 studies reached it within 36 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Maraviroc
Acquired Immunodeficiency Syndrome →